Diffuse large B-cell lymphoma carrying both t(3; 7)(q27; p12) and t(8; 14)(q24; q32)

Internal Medicine

Volumn 50, Issue 8, 2011, Pages 905-908

  Katsura, Yukitaka ^a   Ohta, Ikuyo ^a   Yoshida, Chikashi ^a   Ohtani, Haruo ^a   Komeno, Takuya ^a  

^a NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma; MYC; T(3; 7)(q27; p12); T(8; 14)(q24; q32)

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; METHOTREXATE; MYC PROTEIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CARCINOGENESIS; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHROMOSOME 14; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; COMPUTER ASSISTED TOMOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; DNA-BINDING PROTEINS; GENES, MYC; HUMANS; IKAROS TRANSCRIPTION FACTOR; KARYOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ONCOGENE FUSION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; SALVAGE THERAPY; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 79955566615     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4860     Document Type: Article

References (13)

1. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453: 110-114, 2008.
2. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360: 470-480, 2009.
3. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 27: 5202-5207, 2009.
4. Ichinohasama R, Miura I, Funato T, et al. A recurrent nonrandom translocation (3; 7)(q27; p12) associated with BCL-6 gene rearrangement in B-cell diffuse large cell lymphoma. Cancer Genet Cytogenet 104: 19-27, 1998.
5. Deweindt C, Kerckaert JP, Tilly H, Quief S, Nguyen VC, Bastard C. Cloning of a breakpoint cluster region at band 3q27 involved in human non-Hodgkin's lymphoma. Genes Chromosomes Cancer 8: 149-154, 1993.
6. Kluin PM, Harris NL, Stein H. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: WHO Classification of Tumours of Haemotopoietic and Lymphoid Tissues. 4th ed. Swerdlow SH, Campo E, Harris NL, et al, Eds. WHO Press, Lyon, 2008: 265-266.
7. Stein H, Warnke RA, Chan WC. Diffuse large B-cell lymphoma, not otherwise specified. In: WHO Classification of Tumours of Haemotopoietic and Lymphoid Tissues. 4th ed. Swerdlow SH, Campo E, Harris NL, et al, Eds. WHO Press, Lyon, 2008: 233-237.
8. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106: 1569-1580, 2006.
9. Ogura M, Kagami Y, Taji H, et al. Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma. Int J Hematol 77: 503-511, 2003.
10. Hosokawa Y, Maeda Y, Ichinohasama R, Miura I, Taniwaki M, Seto M. The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t(3; 7)(q27; p12) translocation in a patient with diffuse large B-cell lymphoma. Blood 95: 2719-2721, 2000.
11. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114: 3533-3537, 2009.
12. Akasaka T, Akasaka H, Ueda C, et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 18: 510-518, 2000.
13. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152-3162, 1998.